trends in aml and mds at ash 2021
Published 2 years ago • 441 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
3:02
highlights in aml and mds from eha 2022
-
2:38
managing the progression of mds to aml
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
0:55
the role of rna modifications in mds and aml
-
1:01
novel treatment paradigms for aml at ash 2021
-
2:00
key mds updates from the 2021 ash meeting
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
4:39
aml & mds: mac or ric?
-
53:35
copy number variation and the secret of life - with aoife mclysaght
-
3:16
identifying low- and high-risk aml
-
4:34
the genetics of acute myeloid leukemia (aml)
-
7:27
menin inhibitors in aml: mechanism of action, the current key data, and predicting efficacy
-
1:59
major trial outcomes at ash 2021: panther, agile, and lacewing
-
2:55
prognostic drivers in aml and mds
-
1:09
differences and similarities between mds and aml & how this can inform treatment decisions
-
3:14
hypomethylating agents in mds and aml
-
2:58
feasibility and safety of early discharge in nd aml following intensive induction therapy
-
1:02
the impact of sequencing in aml
-
2:27
improving our understanding of mds for better disease management
-
1:42
novel treatment combinations in aml: what’s to come?
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents